CRMD — CorMedix Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1410098 ·
Last close
$8.40
Market Cap
$659.00M
52W High
$9.09
52W Low
$7.05
ADV30
1,399,674
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 127,427,000 | 105,122,000 | 63,658,000 | 38,601,000 | 815,637,000 | 178,087,000 | 378,588,000 |
| Dec 2025 | 128,615,264 | 107,308,042 | 59,126,248 | 14,020,141 | 826,142,000 | 144,837,000 | 420,835,000 |
| Sep 2025 | 104,275,289 | 93,080,673 | 51,345,966 | 108,562,980 | 750,861,478 | 48,493,076 | 376,732,072 |
| Jun 2025 | 39,736,790 | 37,874,342 | 19,543,505 | 19,827,981 | 252,599,103 | 159,308,966 | 31,968,916 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$197,691,000
Investing CF
$-305,270,000
Financing CF
$220,263,000
CapEx
$-2,979,000
Dividends Paid
—
Buybacks
$-11,092,000
EPS Diluted TTM
$2.13
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-137,974,000
Inventory
$30,731,000
Receivables
$154,807,000
ST Investments
$0
EBIT TTM
$195,802,094
Pretax Income TTM
$185,017,102
Interest Exp TTM
$2,781,999
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$400,054,016
EBITDA
$228,804,992
Free Cash Flow
$119,837,056
Enterprise Value
$649,505,920
Total Cash
$178,087,008
Total Debt
$147,415,008
Shares Out
78,451,891
Trailing EPS
$2.17
Book Value
$5.58
ROE
65.6%
ROA
26.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 311,709,000 | 150,141,000 | 163,055,000 | 826,142,000 | 420,835,000 | — | 175,046,000 |
| Dec 2024 | 43,472,000 | -22,356,000 | -17,930,000 | 118,846,000 | 34,189,000 | — | -50,615,000 |
| Dec 2023 | 0 | -48,957,788 | -46,339,227 | 82,059,957 | 11,917,528 | — | -38,409,480 |
| Dec 2022 | 65,408 | -30,623,968 | -29,701,705 | 62,038,259 | 6,978,523 | — | -24,356,732 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.35
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $666.49M | $8.32 | — |
| RLMD | RELMADA THERAPEUTICS, INC. | $672.97M | $6.41 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $675.67M | $32.07 | — |
| STTK | Shattuck Labs, Inc. | $634.17M | $6.64 | — |
| MNPR | Monopar Therapeutics | $714.12M | $106.60 | — |
News headlines (Yahoo Finance, 1h cache)
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
2026-07-09 21:25 · Yahoo
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?
2026-07-08 13:15 · Yahoo
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
2026-06-30 15:10 · Yahoo
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
2026-06-30 15:07 · Yahoo
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
2026-06-30 15:04 · Yahoo
Within3 Appoints Erin Mistry as Chief Executive Officer
2026-06-22 13:05 · Yahoo
CorMedix (CRMD) Stock Could Be 27.8% Undervalued After Q1 Results And Raised Outlook
2026-06-17 11:12 · Yahoo
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath Momentum - Learn Why
2026-06-16 06:12 · Yahoo
CorMedix Inc. (CRMD) Reports Q1 2026 Results
2026-06-13 18:07 · Yahoo
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
2026-06-08 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.